tiprankstipranks
Pliant Therapeutics price target lowered to $58 from $60 at RBC Capital
The Fly

Pliant Therapeutics price target lowered to $58 from $60 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Pliant Therapeutics to $58 from $60 but keeps an Outperform rating on the shares after its Q4 results. The company’s six-month high-dose 320 mg data on Bexotegrast remain on track for Q2, and a continued delta between drug and placebo arms on lung function alongside good safety should further de-risk the program, the analyst tells investors in a research note. The firm adds that Pliant Therapeutics’ INTEGRIS PSC data in Q3 remains higher risk but likely still overlooked.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PLRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles